Biomira Announces Final Phase 2b Survival Results of Stimuvax®

28 April 2006 Filed under Uncategorized Posted by admin » No Comments


Biomira Announces Final Phase 2b Survival Results of Stimuvax® (formerly known as BLP25 Liposome Vaccine) Trial in Patients With Non-Small Cell Lung Cancer

Results Confirm Median Survical of 30.6 Months in Stage IIIB Patients on Vaccine Versus 13.3 Months in Control Patients

Trackback URL

No Comments

You must be logged in to post a comment.